Log in to save to my catalogue

Safety and efficacy of givinostat in boys with Duchenne muscular dystrophy (EPIDYS): a multicentre,...

Safety and efficacy of givinostat in boys with Duchenne muscular dystrophy (EPIDYS): a multicentre,...

https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_proquest_miscellaneous_2973103924

Safety and efficacy of givinostat in boys with Duchenne muscular dystrophy (EPIDYS): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial

Publication information

Publisher

England: Elsevier Ltd

More information

Scope and Contents

Contents

Duchenne muscular dystrophy, the most common childhood muscular dystrophy, is caused by dystrophin deficiency. Preclinical and phase 2 study data have suggested that givinostat, a histone deacetylase inhibitor, might help to counteract the effects of this deficiency. We aimed to evaluate the safety and efficacy of givinostat in the treatment of Duc...

Alternative Titles

Full title

Safety and efficacy of givinostat in boys with Duchenne muscular dystrophy (EPIDYS): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial

Identifiers

Primary Identifiers

Record Identifier

TN_cdi_proquest_miscellaneous_2973103924

Permalink

https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_proquest_miscellaneous_2973103924

Other Identifiers

ISSN

1474-4422,1474-4465

E-ISSN

1474-4465

DOI

10.1016/S1474-4422(24)00036-X

How to access this item